Search results for " HCV"

showing 10 items of 107 documents

Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver

2012

Background: The prevalence of hepatitis C virus infection increases with advancing age, but elderly hepatitis C virus patients remain an understudied population. Aim: To define the virological, epidemiological and clinical profiles of Italian outpatients aged 65 years and over infected by hepatitis C virus. Methods: We evaluated 1544 anti-hepatitis C virus positive patients aged >=65 years referred to 34 Italian outpatient specialty clinics over a two-year period. Results: The study population included 1134 (73%) early elderly (65-74 years) and 410 (27%) late elderly patients (>=75 years). Late elderly subjects were less likely to have their virus genotyped, their viral load assessed or a h…

Liver CirrhosisMaleAGED PATIENTS; EPIDEMIOLOGY; HCV INFECTION; LIVER DISEASES; ANTI-VIRAL TREATMENTEpidemiologyCross-sectional studyHepacivirusLIVER DISEASESmedicine.disease_causeLiver disease80 and overPrevalenceEPIDEMIOLOGYChronicAged patientsAged 80 and overeducation.field_of_studyhepatitis c elderly italyAge FactorsHCV INFECTIONGastroenterologyliver diseases; hepatitis c elderly italy; hcv infection; epidemiology; aged patientsAlanine TransaminaseHepatitis CViral LoadAGED PATIENTSHepatitis CHCV infectionItalyHCVAged patients; Epidemiology; HCV infection; Liver diseasesPopulation studyFemaleViral loadmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAHepatitis C virusPopulationgeriatricAntiviral AgentsInternal medicinemedicineHumanseducationSettore MED/42 - IGIENE GENERALE E APPLICATALiver diseasesAgedHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAHepatitis C ChronicHepatitis C AntibodiesHepatologymedicine.diseaseSurgeryCross-Sectional StudiesAged patients; Epidemiology; HCV infection; Liver diseases; Age Factors; Aged; Aged 80 and over; Alanine Transaminase; Antiviral Agents; Cross-Sectional Studies; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C Chronic; Humans; Italy; Liver Cirrhosis; Male; Prevalence; Viral Load; Gastroenterology; HepatologyANTI-VIRAL TREATMENTbusiness
researchProduct

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

2007

The effect of achieving a sustained virological response (SVR) following interferon-α (IFNα) treatment on the clinical outcomes of patients with HCV-related cirrhosis is unknown. In an attempt to assess the risk of liver-related complications, HCC and liver-related mortality in patients with cirrhosis according to the response to IFNα treatment, a retrospective database was developed including all consecutive patients with HCV-related, histologically proven cirrhosis treated with IFNα monotherapy between January 1992 and December 1997. SVR was an undetectable serum HCV-RNA by PCR 24 weeks after IFNα discontinuation. HCC was assessed by ultrasound every 6 months. Independent predictors of al…

Liver CirrhosisMaleANTIVIRAL TREATMENTMultivariate analysisCirrhosisHepacivirusdrug therapy/mortality/virologyGastroenterologyCohort StudiesINTERFERON; HEPATITIS C; CIRRHOSIS; CHRONIC HEPATITIS C; ANTIVIRAL TREATMENT; SUSTAINED VIROLOGICAL RESPONSE; Liver cirrhosis.MedicinegeneticsLongitudinal StudiesViralCIRRHOSISHazard ratiovirus diseasesHepatitis CAdult Antiviral Agents; therapeutic use Cohort Studies Female Hepacivirus; genetics Hepatitis C; blood/complications/drug therapy/mortality Humans Interferon-alpha; therapeutic use Liver Cirrhosis; drug therapy/mortality/virology Longitudinal Studies Male Middle Aged Multivariate Analysis RNA; Viral; blood Retrospective Studies Survival Analysis Treatment OutcomeMiddle AgedLiver cirrhosis.Treatment OutcomeSUSTAINED VIROLOGICAL RESPONSEHEPATITIS CLiver Cirrhosis/drug therapy Liver Cirrhosis/virologyRNA ViralFemaleAdultINTERFERONmedicine.medical_specialtyCHRONIC HEPATITIS CAntiviral AgentsbloodInternal medicineHumansRetrospective StudiesSustained virological response interferon-alpha HCV-related cirrhosis:Hepatologybusiness.industryProportional hazards modelInterferon-alphaRetrospective cohort studyblood/complications/drug therapy/mortalityHepatologymedicine.diseaseSurvival Analysisdigestive system diseasesDiscontinuationSurgerytherapeutic useMultivariate AnalysisRNAbusiness
researchProduct

Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals

2018

Background: Despite the dramatic improvement in viral eradication rates that has been reached with direct antiviral agents (DAAs),the real benefit of viral eradication after DAAs on hepatocellular carcinoma (HCC) development is still controversial. Aim: To prospectively assess the risk of HCC occurrence and early recurrence in a large cohort of DAAtreated HCV-cirrhotic patients and to identify potential predictors of HCC development. Methods: We analyzed data prospectively collected from 1927 consecutive HCV-infected cirrhotic patients treated with DAA from January to December 2015 in 10 tertiary liver centers in Italy and followed-up for one year after therapy. 161 patients had a previous …

Liver CirrhosisMaleCirrhosisSustained Virologic ResponseHepatocellular carcinomaDirect antiviral agentsDIRECT ACTING ANTIVIRALSGastroenterologyCohort Studies0302 clinical medicineRisk FactorsChronicIncidence (epidemiology)Liver NeoplasmsGastroenterologyMiddle AgedHepatitis CTumor recurrenceCirrhosis; Direct antiviral agents; HCV; Hepatocellular carcinoma; Aged; Antiviral Agents; Carcinoma Hepatocellular; Cohort Studies; Disease Progression; Female; Hepatitis C Chronic; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Risk Factors; alpha-Fetoproteins; Sustained Virologic ResponseItalyLocalCirrhosis030220 oncology & carcinogenesisHepatocellular carcinomaHCVDisease ProgressionPortal hypertension030211 gastroenterology & hepatologyFemalealpha-FetoproteinsCohort studymedicine.medical_specialtyCarcinoma HepatocellularEarly RecurrenceAntiviral Agents03 medical and health sciencesInternal medicinemedicineHumansneoplasmsAgedCirrhosiHepatologybusiness.industryCarcinomaHepatocellularHepatitis C Chronicmedicine.diseasedigestive system diseasesNeoplasm RecurrenceDirect antiviral agentNeoplasm Recurrence LocalCirrhosis; Direct antiviral agents; HCV; Hepatocellular carcinomabusiness
researchProduct

Reply to: “Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients”

2014

Prof. Kitson’s comments give us the opportunity to clarify some issues that were not completely dealt with in our manuscript. In the study we reported a link between fructose intake and the severity of liver fibrosis in a cohort of Italian patients with genotype 1 chronic hepatitis C (CHC) [1], with an association found for industrial, but not for fruit fructose intake. Our results were in keeping with data already reported in patients with non-alcoholic fatty liver disease [2,3].

Liver CirrhosisMaleHepatologyFruitFRUCTOSE HCVLiver fibrosiHumansFemaleFructoseHepatitis C ChronicHepatitis C
researchProduct

HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome.

2015

Aim: To evaluate similarities and differences in HCV-1 subtypes 1a and 1b in the presenting clinical features and the response to peg-interferon and ribavirin (Peg/RIBA).Patients and methods: A total of 1,233 naïve patients with HCV genotype-1 infection, 159 (13 %) with subtype 1a and 1,074 (87 %) with subtype 1b were treated with Peg-IFN/RIBA at 12 Italian centers. Covariates included in the logistic model were age, gender, BMI, serum alanine aminotransferase, serum gamma-glutamiltranspeptidase (γGT), platelets counts, liver fibrosis, the occurrence of type 2 diabetes, baseline viremia, and IL28B genotype.Results: At multivariate analysis, baseline characteristics differentiating patients …

Liver CirrhosisMaleMultivariate analysisclinical featuresChronic HCV liver diseaseType 2 diabetesSex FactorHepacivirusGastroenterologyPolyethylene GlycolPolyethylene Glycolstherapeutic outcomechemistry.chemical_compoundGenotypeAge FactorSettore MED/12 - GastroenterologiaSustained virologic responseAge Factorsvirus diseasesHCV genotype 1 subtypes (1a and 1b)Hepatitis CRecombinant ProteinMiddle AgedRecombinant ProteinsTreatment OutcomeInterferonRNA ViralFemaleHCV subtypeHumanAdultmedicine.medical_specialtyGenotypeLiver CirrhosiAlpha interferonmacromolecular substancesInterferon alpha-2Antiviral AgentsSex FactorsDiabetes mellitusInternal medicineRibavirinmedicineHumansPeg-interferon and ribavirinAntiviral AgentHepaciviruHepatologybusiness.industryRibavirinInterleukinstechnology industry and agricultureInterferon-alphaHepatologyInterleukinHepatitis C Chronicmedicine.diseaseVirologydigestive system diseaseschemistryDiabetes Mellitus Type 2HCV genotypeHCV genotype 1 subtypes (1a and 1b); clinical features; therapeutic outcomeInterferonshepatitis Cbusiness
researchProduct

Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis

2008

BACKGROUND: While the likelihood of developing hepatocellular carcinoma (HCC) in patients coinfected with both HBV and HCV is increased, the role of previous exposure to HBV as a risk factor associated with tumor occurrence in subjects with HCV-related cirrhosis has not been fully investigated. AIM: To assess whether serum anti-HBc positivity, as a marker of previous HBV exposure, is associated with HCC development in HCV-related positive, hepatitis B surface antigen (HBsAg) negative patients with cirrhosis treated with alfa-interferon (IFN) monotherapy. PATIENTS AND: A database including 883 consecutive patients (557 men, mean age 54.7 yr) with histologically METHODS: proven cirrhosis trea…

Liver CirrhosisMalePathologyCirrhosisAdult Antibodies; Viral; blood Carcinoma; Hepatocellular; blood/pathology/virology Cohort Studies Female Hepatitis B Core Antigens; immunology Hepatitis B virus; immunology Hepatitis C; blood/complications/pathology Humans Liver Cirrhosis; blood/etiology/pathology Liver Neoplasms; blood/pathology/virology Male Middle Aged Retrospective Studies Risk FactorsAntibodies ViralGastroenterologyanti HBcCohort StudiesimmunologyRisk FactorsHBVViralHCCCIRRHOSISLiver NeoplasmsGastroenterologyvirus diseasesHBV HCV COINFECTIONMiddle AgedHepatitis B Core AntigensHepatitis CAdult; Antibodies Viral; Carcinoma Hepatocellular; Cohort Studies; Female; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Risk Factors; GastroenterologyHepatocellular carcinomaHCVFemaleAdultmedicine.medical_specialtyHepatitis B virusCarcinoma Hepatocellularblood/pathology/virologyAntibodiesbloodblood/complications/pathologyInternal medicinemedicineHumansIn patientHEPATOCELLULAR CARCINOMAHEPATOCELLULAR CARCINOMA; HCV; HBV; CIRRHOSIS; HBV HCV COINFECTIONRetrospective StudiesHepatologybusiness.industryCarcinomaCancerHepatocellularmedicine.diseasedigestive system diseasesblood/etiology/pathologybusiness
researchProduct

Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.

2011

Background & Aims Chronic hepatitis C (CHC) and liver fibrosis progress more rapidly in men and menopausal women than in women of reproductive age. We investigated the associations among menopause, sustained virologic response (SVR), and liver damage in patients with CHC. Methods We performed a prospective study of 1000 consecutive, treatment-naive patients 18 years of age and older with compensated liver disease from CHC. Liver biopsy samples were analyzed (for fibrosis, inflammation, and steatosis) before patients received standard antiviral therapy. From women (n = 442), we collected data on the presence, type, and timing of menopause; associated hormone and metabolic features; serum lev…

Liver CirrhosisMaleTime Factorsmedicine.medical_treatmentBiopsyMenopause PrematuremenopauseHepacivirusmedicine.disease_causeGastroenterologySeverity of Illness IndexRisk FactorsOdds RatioProspective StudiesTreatment FailureProspective cohort studymedicine.diagnostic_testGastroenterologyAge FactorsHormone replacement therapy (menopause)Hepatitis CMiddle AgedViral LoadImmunohistochemistryMenopauseItalyLiver biopsyRNA ViralFemaleInflammation Mediatorshcv svr menopauseViral loadAdultmedicine.medical_specialtyantiviral therapy; menopause; prognostic factors; hcv therapyGenotypeHepatitis C virusAntiviral AgentsRisk AssessmentSex FactorsInternal medicinehcvmedicineHumanshcv; ifn; menopauseHepatologybusiness.industryInterleukin-6Tumor Necrosis Factor-alphaOdds ratioHepatitis C Chronicmedicine.diseaseifnEndocrinologyLogistic ModelsbusinessBiomarkersGastroenterology
researchProduct

Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A…

2010

The incidence of de novo development of esophageal varices (EV) in patients with compensated liver cirrhosis has been determined by few studies in the short term and never in the long term. The aims of the present study were to determine the incidence and the risk factors associated with the development of EV and to assess whether antiviral treatment and achievement of sustained virologic response (SVR) may prevent de novo EV development in patients with HCV-induced cirrhosis. We studied 218 patients with compensated EV-free, HCV-induced cirrhosis consecutively enrolled between 1989 and 1992 at three referral centers in Milan, Italy. Endoscopic surveillance was performed at 3-year intervals…

Liver CirrhosisMalemedicine.medical_specialtyCarcinoma HepatocellularCirrhosisEsophageal and Gastric VaricesAntiviral AgentsGastroenterologyLiver diseaseEsophageal varicesRisk FactorsInternal medicinemedicineHumansProspective StudiesProspective cohort studyAgedHepatologybusiness.industryIncidenceLiver NeoplasmsHazard ratiovirus diseasesHepatitis CHepatitis C ChronicMiddle AgedHepatologymedicine.diseasedigestive system diseasesDiscontinuationItalyFemalebusinessFollow-Up StudiesCirrhosis HCV
researchProduct

Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicen…

2017

SummaryBackground Data on HCV-related hepatocellular carcinoma (HCC) early recurrence in patients whose HCC was previously cured, and subsequently treated by direct-acting antivirals (DAAs), are equivocal. Aim To assess the risk of HCC early recurrence after DAAs exposure in a large prospective cohort of HCV-cirrhotic patients with previous successfully treated HCC, also looking for risk factors for cancer early recurrence. Methods We enrolled 143 consecutive patients with complete response after curative treatment of HCC, subsequently treated with DAAs and monitored by the web-based RESIST-HCV database. Clinical, biological, and virological data were collected. The primary endpoint was the…

Liver CirrhosisMalemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/09 - Medicina InternaEarly RecurrenceDIRECT ACTING ANTIVIRALSAntiviral AgentsGastroenterologyhepatocellular carcinoma (HCC)03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineClinical endpointCarcinomaHumansPharmacology (medical)Prospective StudiesProspective cohort studyneoplasmsComplete responseAgedhepatocellular carcinoma (HCC) HCV directacting antivirals (DAAs)Settore MED/12 - GastroenterologiaSettore MED/08 - ANATOMIA PATOLOGICAHepatologybusiness.industrydirectacting antivirals (DAAs)Liver NeoplasmsCarcinomaGastroenterologyCancerHepatocellularMiddle Agedmedicine.diseaseHepatitis Cdigestive system diseasesNeoplasm RecurrenceLocal030220 oncology & carcinogenesisHepatocellular carcinomaHCVCatheter AblationFemale030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusiness
researchProduct

Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience

2019

INTRODUCTION: The Baveno VI consensus guidelines and an expanded algorithm suggest that transient elastography (TE) and platelet (PLT) count can be used to identify patients with cirrhosis who can avoid esophagogastroduodenoscopy (EGD). The primary aims of this study were to assess the ability of a simple algorithm, which uses only laboratory parameters, to predict medium/large esophageal varices (EV) in patients with hepatitis C virus (HCV) and cirrhosis from the Rete Sicilia Selezione Terapia-HCV (RESIST-HCV) cohort and to compare the performance of the algorithm with Baveno VI and Expanded Baveno VI criteria. The secondary aim was to assess the role of TE in ruling out large EV. METHODS:…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisBAVENO VI CRITERIA PORTAL-HYPERTENSION CONSENSUS WORKSHOP LIVER STIFFNESS PLATELET COUNT CIRRHOSIS DIAGNOSIS;Esophageal and Gastric Varices03 medical and health sciences0302 clinical medicineRESIST-HCVmedicineesophageal varicesHumansBaveno VIEndoscopy Digestive SystemSerum AlbuminAgedHepatologymedicine.diagnostic_testPlatelet CountEsophagogastroduodenoscopybusiness.industryfungiGastroenterologyReproducibility of Resultsfood and beveragesHepatitis C ChronicMiddle Agedmedicine.diseasetransient elastographyEndoscopyLogistic ModelsCIRRHOSIS PORTAL HYPERTENSION VARICES STIFFNESS030220 oncology & carcinogenesistransient elastography esophageal varices HCV RESIST-HCV Baveno VIMultivariate AnalysisHCVElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologyRadiologyGastrointestinal HemorrhagebusinessVaricesTransient elastographyAlgorithms
researchProduct